Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections

• DOI: 10.1128/spectrum.03108-23
• Publication Date: 2024-01-11T14:02:38Z
• Authors: Amer El Ghali; Ashlan J. Kunz Coyne; Kristen Lucas; Molly Tieman; Xhilda Xhemali; Suet-ping Lau; Gabriela Iturralde; Andrew Purdy; Dana J. Holger; Esther Garcia; Michael P. Veve; Michael J. Rybak
• Keywords: Interquartile range; Acinetobacter baumannii; Carbapenem; Medical record

Multi-drug resistant gram-negative bacteria present a significant global health threat. Cefiderocol (CFDC), siderophore cephalosporin, has shown potential in combating this threat, but with the currently available data, its role therapy remains poorly defined. This multi-center, retrospective cohort study evaluated real-world application of CFDC across six U.S. medical centers from January 2018 to May 2023. Patients aged ≥18 years and who had received ≥72 hours were included. The primary outcome was composite clinical success: survival at 30 days, absence symptomatic microbiologic recurrence days following treatment initiation, resolution signs symptoms. Secondary outcomes included time on-treatment non-susceptibility CFDC. A total 112 patients included, median (interquartile range [IQR]) APACHE II scores 15 (19-18). Clinical success observed 68.8% patients, mortality rate 16.1% comparable rates infected carbapenem-resistant infections. most common isolated organisms